The small molecule anti-cancer therapy developer BlossomHill (BLSM.US) has set an IPO pricing of $15-17 per share, aiming to raise $125 million.

Zhitong Finance APP has learned that BlossomHill Therapeutics, a biotech company focused on developing small molecule cancer therapies and currently in the Phase II clinical preparation stage, announced the terms of its initial public offering (IPO) on Monday. The company plans to issue 7.8 million shares at a price range of $15 to $17 per share, aiming to raise $125 million. The company plans to list on NASDAQ under the ticker symbol BLSM.